HuGE Literature Finder
Records
1
-
4
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British journal of cancer 2017 Aug . Lévi Francis, Karaboué Abdoulaye, Saffroy Raphaël, Desterke Christophe, Boige Valerie, Smith Denis, Hebbar Mohamed, Innominato Pasquale, Taieb Julien, Carvalho Carlos, Guimbaud Rosine, Focan Christian, Bouchahda Mohamed, Adam René, Ducreux Michel, Milano Gérard, Lemoine Antoinet |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. British journal of cancer 2013 Sep 109 (6): 1420-7. Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36. Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 21, 2023
- Content source: